SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: Truist Securities BioPharma Symposium – 1x1 onlyDate: Thursday, November 6, 2025Location: New York, NY ...

WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in November: 2025 Truist Securities BioPharma Symposium, New York, NYThursday, November 6, 2025, Panel - 8:10 a.m. ETStifel 2025 Healthcare Confere ...

Core Insights - Dupixent (dupilumab) has been awarded the "Best Biotechnology Product" of 2025 by the Galien Foundation, recognizing its significant scientific innovation and impact on various allergic and atopic conditions [1][2] - It is the first and only therapy specifically targeting the IL-4 and IL-13 signaling pathways, which are key drivers of type 2 inflammation [1][2] Company Overview - Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on developing life-transforming medicines for serious diseases [23] - The company utilizes proprietary technologies, such as VelocImmune, to create optimized fully human antibodies [22][24] Product Details - Dupixent is approved for eight indications globally, including atopic dermatitis, asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, bullous pemphigoid, prurigo nodularis, and chronic obstructive pulmonary disease (COPD) [3][6] - More than 1 million patients are currently being treated with Dupixent worldwide [2][6] Scientific Significance - Dupixent was developed based on a hypothesis that many allergic and atopic diseases are driven by excess IL-4 and IL-13, with Phase 3 trials demonstrating significant clinical benefits [2][5] - It is the first dual blocker of IL-4 and IL-13 approved by the U.S. FDA, highlighting its unique position in the market [2][5] Clinical Development - Dupixent has been studied in over 60 clinical trials involving more than 10,000 patients, focusing on chronic diseases associated with type 2 inflammation [8][9] - The product is jointly developed by Regeneron and Sanofi under a global collaboration agreement [7] Future Prospects - Regeneron and Sanofi are exploring additional indications for Dupixent in Phase 3 trials, including chronic pruritus of unknown origin and lichen simplex chronicus [9]

Company Overview - AirSculpt Technologies, Inc. is an industry leader in premium body contouring procedures [1] - The company offers a next-generation body contouring treatment that emphasizes comfort and precision, available exclusively at its offices [3] Financial Results Announcement - AirSculpt will report its third quarter 2025 financial results before the market opens on November 7, 2025 [1] - A conference call will follow the results announcement at 8:30 a.m. Eastern Time on the same day [1] Conference Call Access - The conference call can be accessed via a toll-free domestic number or an international number, using a specific conference ID [2] - A live webcast of the call will be available on the investor relations section of the AirSculpt website, with a replay accessible for approximately 90 days [2]

Core Points - Castellum, Inc. has been awarded a $66.2 million contract for logistics, engineering, and cyber support services for the Naval Air Warfare Center Aircraft Division, marking its first full and open prime contract win without small-business set-aside restrictions and the second-largest contract in the company's history [1][2][3] Group 1: Contract Details - The awarded contract is a five-year agreement aimed at supporting the Mission Operations & Integration Department at NAWCAD Lakehurst, which is responsible for Navy Aircraft Platform Support Equipment and Aircraft Launch Recovery Equipment [1][3] - Specialty Systems, Inc. will provide services related to logistics, engineering, and cyber work products for aircraft carriers and air-capable ships [1][3] Group 2: Company Strategy and Performance - The contract win reflects the effectiveness of Castellum's strategy to focus on full and open opportunities as it transitions to a larger business model [4] - Castellum has secured two major prime contracts in the past seven months, including a $103 million contract announced in February, indicating strong growth and competitiveness in the market [5] Group 3: Leadership and Team Recognition - The leadership at Castellum emphasizes the dedication and skills of its professionals, attributing the contract win to their hard work and commitment to providing world-class service [6] - The company expresses confidence in its team and the positive impact of these contracts on its mission capabilities and overall business growth [5][6]

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund (the “Fund”) (NYSE: CCIF), an externally managed closed-end fund focused on investing in primarily equity and junior debt tranches of collateralized loan obligations, has entered into a Purchase Agreement with certain institutional investors for the purchase and sale of approximately 17,500 shares of the Fund’s 7.25% Series E Convertible Preferred Shares due 2030 (the “Convertible Preferred Shares”), liquidation preference $1,000.00 per ...

Core Insights - LyondellBasell Industries reported a net loss of $890 million for Q3 2025, with diluted loss per share of $2.77, significantly down from a profit of $573 million in Q3 2024 [1][6][31] - The company recognized $1.2 billion in identified items, which included non-cash asset write-downs and costs related to various initiatives, impacting earnings by $3.78 per share [4][6] - EBITDA for Q3 2025 was $(480) million, but $835 million when excluding identified items, indicating operational challenges [4][6] Financial Performance - Sales and other operating revenues for Q3 2025 were $7.727 billion, a slight increase from $7.658 billion in Q2 2025 but down from $8.604 billion in Q3 2024 [1][4] - The net loss for the nine months ended September 30, 2025, was $598 million, compared to a profit of $1.970 billion for the same period in 2024 [1][4] - Cash from operating activities was $983 million with a cash conversion rate of 135% during Q3 2025 [4][9] Operational Highlights - The Olefins and Polyolefins Americas segment saw improved profitability due to increased olefins margins and higher sales volumes, despite a decrease in polyethylene spreads [7] - The Intermediates and Derivatives segment benefited from increased octane blend premiums and lower raw material prices, although styrene margins declined [8] - The company is executing a Cash Improvement Plan aimed at achieving $600 million in savings for 2025 and a minimum of $1.1 billion by the end of 2026 [5][10] Strategic Initiatives - LyondellBasell is focusing on operational and financial discipline, with plans to reduce capital expenditures to $1.2 billion in 2026 while supporting the construction of a chemical recycling plant in Germany [10] - The company is advancing its portfolio transformation with the sale of four European assets, which has received regulatory approvals [10] - The company plans to idle its larger cracker in Wesseling, Germany, and a propylene oxide/styrene monomer unit in Channelview, Texas, for maintenance and alignment with global demand [12][13] Market Outlook - The fourth quarter is expected to be impacted by seasonality and lower operating rates, with pressures on integrated polyolefins margins due to rising natural gas and feedstock costs in North America [11] - Weak industrial and consumer demand is anticipated to persist in Europe, although global capacity rationalizations may support a more constructive mid-term outlook for the industry [11]

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (the "Company") (Nasdaq: CGBD) today announced that it intends to redeem all $85,000,000 aggregate principal amount of its outstanding 8.20% Notes due 2028 (the "2028 Notes") on December 1, 2025 (the "Redemption Date"). A notice of redemption will be mailed to all registered holders of the 2028 Notes by U.S. Bank Trust Company, National Association, as successor trustee to The Bank of New York Mellon Trust Company, N.A (the "Trustee") ...

NANO Nuclear Energy Inc. Figure 1 - NANO Nuclear Energy Inc. Founder and Chairman Jay Yu will participate in multiple speaking sessions from November 3-6 at ADIPEC 2025 in Abu Dhabi, UAE, the world’s largest energy event. ADIPEC will host more than 16,500 delegates, 1,800 speakers, and over 205,000 attendees for high-level discussions shaping the future of energy. New York, N.Y., Oct. 31, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advance ...

Group 1 - Mark Draper, an employee-elected member of the Board of Directors, will resign from his position at Scandinavian Tobacco Group A/S on 31 October 2025 [2] - Hanne Malling, the Trademark Manager, will replace Mark Draper on the Board of Directors starting 1 November 2025 for the remainder of the current term, which lasts until the annual general meeting in 2027 [2]